Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/first-patient-enrolled-in-a-phase-2-study-in-patients-with-type-2-diabetes-with-olatecs-nlrp3-inhibitor-dapansutrile-302194959.html
https://www.businesswire.com/news/home/20210428006008/en/Olatec-Therapeutics-Announces-Results-Showing-Dapansutrile-Reduces-Tumor-Growth-in-a-Mouse-Model-of-Melanoma#:~:text=%E2%80%9COur%20studies%20using%20a%20melanoma,growth%20was%20reduced%20in%20mice.